For example, MRI metrics such as relative cerebral blood volume (rCBV) and apparent diffusion coefficient (ADC) have been useful in monitoring treatment response and providing predictive value in glioma patients.28–31 However, early MRI biomarkers of treatment efficacy in IDH-mutant gliomas following IDH inhibition remain largely unknown. This evidence concerns the gene IDH1 and glioma.